Pressroom

USC has received $5.8 million from Gates Ventures and the American Heart Association to launch a lab aimed at diversifying clinical trials.

A new USC Schaeffer Center paper highlights tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, that are costing patients, employers and the government billions for what should be inexpensive medicines.

Researchers observed a 23% drop in opioid prescriptions and a 27% increase in prescriptions for naloxone.

Populations underrepresented in clinical trials face worse health outcomes that will cost the U.S. trillions of dollars over the next three decades.

Although big data is revolutionizing healthcare, its potential has been limited by underrepresentation of vulnerable populations, including marginalized racial and socioeconomic groups that are at higher risk for poor health outcomes.

Rosalie Liccardo Pacula presented findings at the U.N. Commission on Narcotic Drugs side event.

Among older Americans surveyed in the weeks after FDA approval of aducanumab, few could correctly answer true or false questions about the first new Alzheimer’s drug in decades.

Latino immigrants, especially noncitizens, face a much greater risk of dying than their U.S.-born peers, USC researchers have found.

These findings further reinforce the need for targeted support and resources for families and patients living with Alzheimer’s and other dementias.

A new USC study shows herd immunity is unlikely to happen.